Ownership history in Braslyn Ltd. Β· 4 quarters on record
This page tracks every 13F SEC filing in which Braslyn Ltd. reported a position in Tango Therapeutics Inc. (TNGX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Braslyn Ltd. underperformed the S&P 500 by β24.7% annually on this TNGX position. Maximum drawdown during holding period: β10.3%.
β Significantly underperformed the S&P 500 by 24.7% ann.
2 quarters analyzed
π No drawdown exceeding 20% during the holding period β exceptionally stable.
1 add Β· 0 trims. Bought during 0 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 1.64% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size